Lv Iena Mm
"ACCESS Europe will provide important clinical care and health economic information about the MitraClip(R) therapy," said Professor Tamburino, chair of cardiology, cardiology department, cardiac catheterization and interventional cardiology, Ferrarotto Hospital, University of Catania, Sicily. "This data will allow us to further understand the benefits of the MitraClip(R) therapy for patients with mitral regurgitation and the health economic benefits of a less invasive alternative for patients suffering from MR."
About the MitraClip(R) Procedure
European Post Market Observational Study Intended to Collect Data to Demonstrate the Clinical and Health Economic Benefits of the MitraClip(R) Therapy for Patients with Mitral Regurgitation
Evalve, Inc. Release: MitraClip(R) Therapy Data Shows Important Clinical Benefit in High Risk Patients With Functional Mitral Regurgitation at 12 Month Follow Up Medical device Maker Unilife Medical Solutions to Bring 33 Jobs to York CountyEvalve, Inc. First Dutch Patients Treated With the Percutaneous MitraClip(R) System Use of the MitraClip(R) System Continues to Expand in the European Union Home Medical Equipment Providers Face More Cuts
Founded in 1999, Evalve, Inc., headquartered in Menlo Park, Calif., has developed a proprietary system which enables percutaneous repair of cardiac valves. The company's initial products are intended to reduce the risks, trauma and costs associated with current open, arrested heart surgical options.
About Evalve, Inc.
Evalve, Inc. Two Year Vuitton Bags 2018
Inc. Raises $15 Million
"Initiating enrollment in ACCESS Europe is another important milestone for Evalve and the MitraClip therapy," said Ferolyn Powell, president and chief executive officer of Evalve. "This study is designed to provide meaningful clinical and health economic information building on the important foundation of data already generated in the US. The early experience in Europe has been primarily the treatment of patients who are either non surgical candidates, or higher risk surgical patients, with functional MR."
Percutaneous mitral repair with Evalve's MitraClip(R) device is performed by physicians in the catheterization laboratory. The heart beats normally during the procedure, and therefore does not require a heart lung bypass machine. In addition to improving blood flow through the heart, the procedure may also relieve symptoms such as fatigue and shortness of breath that often affect patients with significant MR. After treatment, patients generally recover quickly. The MitraClip(R) Lv Iena Mm device may improve quality of life and may help MR patients avoid or delay surgery, having preserved surgical options (valve repair or replacement) should surgery become necessary.
Follow Up Data Demonstrates Preservation of Adequate Mitral Valve Area in Patients Treated with the MitraClip(R) System EVEREST Data Shows that the MitraClip(R) Therapy does not produce Clinically Significant Mitral Stenosis CeraPedics, Louis Vuitton Alma Bb Price
Evalve Inc Release First Patients Enrolled in the Access Europe Study of The MitraClipR Therapy
Evalve received CE Mark approval for the MitraClip(R) system last year, and has worked with hospitals across Europe to establish training programs in support of the European roll out. Patients have been treated in Italy, Germany, the United Kingdom, the Netherlands and Switzerland.
MR affects millions of people worldwide and is the most common type of heart valve insufficiency in Europe and the United States. In Europe, similar to the US, there are approximately 250,000 new diagnoses of significant MR each year; however, only 20 percent or approximately 50,000 of these patients undergo surgery each year. Non surgical patients and many of the higher risk surgical patients continue to be affected by the chronic volume overload caused by MR, which requires the heart to work harder, which may lead to heart failure and hospitalization. at Ferrarotto Hospital at Catania University in Sicily, Italy.
two comparator groups, one which includes medically managed heart failure patients with MR and another which includes patients who are undergoing mitral valve surgery for MR.
MENLO PARK, Calif., April 6 /PRNewswire/ Evalve, Inc., the leader in the development of devices for the percutaneous repair of cardiac valves, announced today the first enrollment in the ACCESS Europe study, a post market observational study of the MitraClip(R) therapy in Europe. The MitraClip(R) system is the first commercially available treatment option for non surgical mitral valve repair for patients suffering from the effects of functional and degenerative mitral regurgitation (MR).
The MitraClip(R) system is currently undergoing clinical evaluation in the United States and Canada. The MitraClip(R) system is available for commercial distribution in the European Union.
The ACCESS Europe study will evaluate the MitraClip(R) therapy in the continuum of care available to patients with MR. Patients will be evaluated at baseline through 12 months after enrollment. As many as 20 institutions within Europe will participate and up to 300 patients treated with the MitraClip(R) device will be enrolled. In addition, information will be collected in Louis Vuitton Bags 2018 Prices
Lv Iena Mm
Vuitton Neverfull GmHome
Louis Vuitton Evidence Sunglasses Price
Adidas Climacool Boat Lace Review
Louis Vuitton Tote Bag
Lv Artsy Sizes
Clutch Louis Vuitton
Adidas Basketball Shoes Best
Louis Vuitton Neverfull Mm
Louis Vuitton Mens Wallet Replica
Adidas Climacool 1 Trainers Mens
Louis Vuitton Key Pouch Empreinte
Adidas Climacool Coca Cola
Urban Satchel Louis Vuitton Bag
Adidas Pro Model Basketball Shoes 2010
/ Lv Iena Mm